Prognose

Das durchschnittliche Kursziel der Analysten beträgt +0,85€(−72,13%). Der Median liegt bei +0,85€(−72,13%).

Kaufen	4
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit
AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company announced its acceptance into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successfully demonstrated initial proof-of-concept in integrating artificial intelligence (“AI”)-enabled capabilities across its portfolio of Enterprise Health and Personal Health exoskeleton devices.» Mehr auf globenewswire.com
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.» Mehr auf globenewswire.com
Ekso Bionics Announces Reverse Stock Split
SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Ekso Bionics Holdings einen Umsatz von 3,12 Mio€ und ein Nettoeinkommen von −2,67 Mio€

(EUR)	März 2025	YOY
Umsatz	+3,12 Mio	10,36%
Bruttoeinkommen	+1,67 Mio	7,65%
Nettoeinkommen	−2,67 Mio	15,89%
EBITDA	−3,18 Mio	15,70%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+6,27 Mio€
Anzahl Aktien	2,40 Mio
52 Wochen-Hoch/Tief	+19,58€ - +2,33€
Dividenden	Nein
Beta	0,89
KGV (PE Ratio)	−7,20
KGWV (PEG Ratio)	−0,54
KBV (PB Ratio)	+6,12
KUV (PS Ratio)	+0,42